• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Lialda (mesalamine) delayed-release tablet

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- October 2009


Summary View



Post Marketing Experience

The following adverse reactions have been identified during post-approval use of Lialda in clinical practice. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Cardiac Disorders: Myocarditis and pericarditis.
  • Hepatobiliary Disorders: Hepatitis
  • Renal Disorders: Interstitial nephritis
  • Respiratory, Thoracic and Mediastinal Disorders: Hypersensitivity pneumonitis (including interstitial pneumonitis, allergic alveolitis, eosinophilic pneumonitis).